

sTable1. Efficacy of different dosage of daridorexant

	Daridorexant				
Mean (n)	Placebo	5 mg	10 mg	25 mg	50 mg
TST, min					
Change at days 1 and 2	41.3(114)	53.3(116)	68.0(112)	78.2(115)	92.5(117)
Change at month 1	34.2(678)	53.9(60)	43.8(365)	51.5(679)	62.0(371)
Change at month 3	37.3(618)	NA	37.3(307)	45.7(619)	61.2(310)
ISI					
Change at month 1	-3.8(678)	-7.4(60)	-5.2(365)	-4.9(679)	-5.6(371)
Change at month 3	-5.4(618)	NA	-7.0(307)	-6.5(619)	-7.4(310)
Daytime alertness - mm					
Change at days 1 and 2	14.2(54)	9.5(56)	17.1(54)	17.2(55)	13.2(56)
Change at month 1	7.8(678)	15.1(60)	10.6(365)	9.5(679)	11.5(371)
Change at month 3	12.3(618)	NA	14.4(307)	15.4(619)	16.2(310)
Morning sleepiness - mm					
Change at days 1 and 2	9.6(54)	8.3(56)	14.6(54)	14.4(55)	13.8(56)
Change at month 1	6.9(675)	14.7(60)	10.1(364)	9.7(678)	11.2(369)
Change at month 3	11.5(615)	NA	13.5(306)	14.9(618)	15.3(308)
Ability to function - mm					
Change at days 1 and 2	12.1(54)	11.1(56)	15.2(54)	17.6(55)	13.4(56)
Change at month 1	7.4(678)	15.5(60)	10.4(365)	8.9(679)	12.9(371)
Change at month 3	11.8(618)	NA	13.4 (307)	14.3(619)	17.3(310)

sTable2. Safety of different dosage of daridorexant

n (%)	Placebo (n = 733)	Daridorexant			
		5 mg (n = 114)	10 mg (n = 418)	25 mg (n = 733)	50 mg (n = 425)
Participants with adverse event* ($\geq 2\%$ in any group)					
Nasopharyngitis	40 (0.05)	2 (0.02)	35 (0.08)	34 (0.05)	24 (0.06)
Headache	25 (0.03)	8 (0.07)	17 (0.04)	43 (0.06)	25 (0.06)
Fatigue	7 (0.01)	1 (0.02)	3 (0.01)	21 (0.03)	11 (0.03)
Participants with ≥ 1 serious adverse event	11 (0.02)	0 (0)	5 (0.01)	5 (0.01)	4 (0.01)